- All patients with TNBC:
- Should be considered for a clinical trial
- Taxanes, carboplatin, eribulin, and capecitabine:
- Are some of the commonly used standard chemotherapeutic drugs
- In general, medical oncologists recommend single-agent sequential therapy
- Combination regimens:
- Have not shown an improvement in DFS or OS
- If the patient has a BRCA mutation:
- He / she could be considered for a PARP inhibitor trial
- Based on the Olympiad trial:
- The PARP inhibitor olaparib:
- Has shown improvement in progression-free survival
- Several other PARP inhibitors such as niraparib and veliparib are being investigated in clinical trials:
- An ongoing SWOG trial (SWOG 1416):
- Is looking at the role of veliparib in mTNBC patients treated with cisplatin
- If the patient has a mismatch repair–deficient tumor or a tumor with microsatellite instability:
- He or she could be considered for pembrolizumab based on recent FDA approval of pembrolizumab in the tumor agnostic setting
- In about 10% of patients, next-generation sequencing may also give a genomically driven clinical trial option
#Arrangoiz #CancerSurgeon #BreastSurgeon #SurgicalOncologist #ComplexSurgicalOncology #BreastCancer #TripleNegativeBreastCancer #TNBC #Miami #Mexico #Teacher #Surgeon #MountSinaiMedicalCenter #MSMC
Like this:
Like Loading...
Related
Published by Rodrigo Arrangoiz MS, MD, FACS, FSSO
My name is Rodrigo Arrangoiz I am a breast surgeon/ thyroid surgeon / parathyroid surgeon / head and neck surgeon / surgical oncologist that works at Center for Advanced Surgical Oncology in Miami, Florida.
I was trained as a surgeon at Michigan State University from (2005 to 2010) where I was a chief resident in 2010. My surgical oncology and head and neck training was performed at the Fox Chase Cancer Center in Philadelphia from 2010 to 2012. At the same time I underwent a masters in science (Clinical research for health professionals) at the University of Drexel. Through the International Federation of Head and Neck Societies / Memorial Sloan Kettering Cancer Center I performed a two year head and neck surgery and oncology / endocrine fellowship that ended in 2016.
Mi nombre es Rodrigo Arrangoiz, soy cirujano oncólogo / cirujano de tumores de cabeza y cuello / cirujano endocrino que trabaja Center for Advanced Surgical Oncology en Miami, Florida.
Fui entrenado como cirujano en Michigan State University (2005 a 2010 ) donde fui jefe de residentes en 2010. Mi formación en oncología quirúrgica y e n tumores de cabeza y cuello se realizó en el Fox Chase Cancer Center en Filadelfia de 2010 a 2012. Al mismo tiempo, me sometí a una maestría en ciencias (investigación clínica para profesionales de la salud) en la Universidad de Drexel. A través de la Federación Internacional de Sociedades de Cabeza y Cuello / Memorial Sloan Kettering Cancer Center realicé una sub especialidad en cirugía de cabeza y cuello / cirugia endocrina de dos años que terminó en 2016.
View all posts by Rodrigo Arrangoiz MS, MD, FACS, FSSO
Rodrigo Arrangoiz MS, MD, FACS, FSSO 